Class Action Lawsuit Against Capricor Therapeutics Raises Concerns for Shareholders

In recent developments, investors in Capricor Therapeutics, Inc., trading on NASDAQ under the ticker symbol CAPR, have been alerted about a securities class action lawsuit that could impact those who held shares between December 17, 2025, and July 26, 2026. This legal undertaking raises serious questions about the integrity of clinical trial protocols and statistical methods disclosed to the public and the FDA.

Background of the Lawsuit

On September 17, 2026, SueWallSt officially notified shareholders about the pending class action. According to the lawsuit, Capricor Therapeutics allegedly failed to adhere to important blinding and protocol standards during its Phase 3 HOPE-3 clinical trial. This trial, aimed at evaluating the efficacy of the drug deramiocel for Duchenne muscular dystrophy, has faced scrutiny regarding the transparency and reliability of its results, with the FDA noting deviations from established procedures.

Shareholders are rightly concerned after observing a drastic decline in Capricor's stock price, which plummeted from $19.70 on July 24, 2026, to $4.19, indicating a staggering loss of around 78.7%. This has raised alarm bells and prompted affected investors to explore their options for potential recovery, especially as motions for lead plaintiffs must be submitted by September 28, 2026.

Allegations of Deviation from Protocol

The crux of the lawsuit revolves around claims that the final clinical study protocol, designated as Protocol 9.0, diverged from the necessary statistical analysis plan. Specifically, allegations state that changes were made to the trial's pre-specified blinding processes, leading to unapproved alterations in the way results were interpreted. Such alterations have serious implications, especially since they were allegedly instigated just before pivotal moments in the study, leading many to believe that key data points were not presented truthfully.

FDA Responses to Trial Conduct

The FDA has pointed out that various subsequent versions of the statistical analysis plan (SAP) were created after the double-blind phase of the study had concluded. This raised questions over the legitimacy of primary endpoint definitions and analytical methods, which further complicates the case surrounding the purported miscommunication surrounding the trial's results. Notably, the FDA observed that certain conversions between raw scores and percentage changes lacked scientific justification and deemed them potentially misleading.

Furthermore, alarming findings emerged regarding adverse reactions; 42% of patients receiving deramiocel experienced hypersensitivity compared to just 15% in the placebo group. This cast a shadow of doubt on the effectiveness of the treatment, potentially leading to investors feeling misled.

Investor Concerns

Shareholders have voiced a multitude of concerns regarding the information communicated by Capricor. Allegations suggest that the company excessively emphasized statistically significant outcomes while concealing critical trial conduct issues until an advisory committee had already cast a 9-3 vote against efficacy support. This led to a sharp decline in stock value after unfavorable FDA briefing documents were made public on July 27, 2026.

Joseph E. Levi, Esq. commented on the importance of the allegations, stating, "The complaint raises serious questions about whether investors received accurate information regarding how the HOPE-3 statistical analysis plan was finalized. Allegations of deviating from established blinding processes, if substantiated, are critical to any investor contemplating the pending BLA."

Participation and Next Steps for Investors

Investors who wish to explore their eligibility to join the CAPR class action lawsuit must ensure they have documentation of their trades, including purchase dates and prices. Regardless of whether they still hold the shares, individuals who invested between the specified dates may qualify for recovery.

To participate, shareholders are encouraged to connect with SueWallSt, which operates under the prominent law firm Levi & Korsinsky LLP. This firm has a strong track record in securing significant settlements for harmed investors and is currently offering a no-cost consultation for potentially affected stakeholders. Interested parties should reach out at [email protected] or call (888) SueWallSt for more information about their rights and options.

Conclusion

The allegations surrounding Capricor Therapeutics serve as a fundamental reminder of the importance of transparency in clinical trials and the implications that arise when proper protocols are not followed. As the legal processes unfold, affected investors are urged to remain informed and take necessary actions to protect their rights and potential financial recoveries. Time is of the essence as the deadlines loom, and consulting legal expertise could provide the guidance needed during this complex situation.